Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1995-05-26
1997-05-06
Wax, Robert A.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 2, 514 8, 424 851, 424 852, 424 855, 530350, 530351, 530826, 930141, A61K 3820, A61K 3816, C07K 1405, C07K 1454
Patent
active
056271557
ABSTRACT:
BCRF1 proteins are provided for treating conditions associated with excessive production of IFN-.gamma.. Also provided are expression vectors for producing BCRF1 proteins. Compositions of the invention are useful in treating a variety of disorders, including allergy, psoriasis, tissue rejection, and MHC-linked autoimmune diseases.
REFERENCES:
R. Baer, et al., "DNA sequence and expression of the B95-8 Epstein-Barr virus genome," Nature, 310:207-211, Jul. 19, 1984.
Andrew G.D. Bean, et al., "Interleukin 10 Protects Mice against Staphylococcal Enterotoxin B-Induced Lethal Shock," Infection and Immunity, 61(10):4937-4939, Nov. 1993.
Rene de Waal Malefyt, et al., "Interleukin 10(IL-10) Inhibits Cytokine Synthesis by Human Monocytes: An Autoregulatory Role of IL-10 Produced by Monocytes," J. Exp. Med., 174:1209-1220, Nov. 1991.
Joakim Dillner and Bengt Kallin, "The Epstein-Barr Virus Proteins," Advances in Cancer Research, 50:95-158, 1988.
David F. Fiorentino, et al., "IL-10 Inhibits Cytokine Production By Activated Macrophages," The Journal of Immunology, 147 (11):3815-3822, Dec. 1, 1991.
Maureen Howard, et al., "Interleukin 10 Protects Mice from Lethal Endotoxemia," J. Exp. Med., 117:1205-1211, Apr. 1993.
Jay B. Horowitz, et al., "Autocrine growth inhibition of a cloned line of helper T. cells," Proc. Natl. Acad. Sci. USA, 83:1886-1890, Mar. 1986.
Di-Hwei Hsu, et al., "Differential effects of IL-4 and IL-10 on IL-2-induced IFN-.gamma. synthesis and lymphokine-activated killer activity," J. of Immunol., 6:663-669, Jan. 27, 1992.
Di-Hwei Hsu, et al., "Expression of Interleukin-10 Activity by Epstein-Barr Virus Protein BCRF1," Science, 250:830-832, Nov. 9, 1990.
Graham S. Hudson, et al., "The Short Unique Region of the B95-8 Epstein-Barr Virus Genome," Virology, 147:81-98, 1985.
Arnaud Marchant, et al., "Interleukin-10 controls interferon-.gamma. and tumor necrosis factor production during experimental endotoxemia," Eur. J. Immunol., 24:1167-1171, 1994.
Hugh O. McDevitt, "The Molecular Basis of Autoimmunity," Clinical Research, 34:163-175, 1985.
Kevin W. Moore, et al., "Homology of Cytokine Synthesis Inhibitory Factor (IL-10) to the Epstein-Barr Virus Gene BCRF1," Science, 248:1230-1234, Jun. 8, 1990.
David A. Thorley-Lawson, "Immunological responses to Epstein-Barr virus infection and the pathogenesis of EBV-induced diseases," Biochimica et Biophysica Acta, 948:263-286, 1988.
Giovanna Tosato, "The Epstein-Barr Virus and the Immune System," Advances in Cancer Research, 49:75-125, 1987.
P. Vieira, et al., "Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: Homology to Epstein-Barr virus open reading frame BCRF1," Proc. Natl. Acad. Sci. USA, 88:1172-1176, Feb. 1991.
Kondo et al. (1994) "Interleukin-10 inhibits the elicitation phase of allergic contact hypersensitivity" J. Investig. Dermatol. 103:811-814.
David F. Fiorentino, et al., "Two types of mouse T helper cell IV. Thy 2 clones secrete a factor that inhibits cytokine production by Th1 clones," Journal of Experimental Medicine, 170:2081-2095, Dec. 1989.
Ning Fei Go, et al., "Interleukin 10, a novel B cell stimulatory factor: Unresponsiveness of X chromosome-linked immunodeficiency B cells," Journal of Experimental Medicine, 172(6):1625-1631, Dec. 1, 1990.
Gunnar von Heijne, "A new method for predicting signal sequence cleavage sites," Nucleic Acids Research, 14(11):4683-4690, 1986.
Kastelein Robert A.
Moore Kevin W.
Bugaisky G. E.
Ching Edwin P.
Dow Karen B.
Macevicz Stephen C.
Schering Corporation
LandOfFree
BCRF1 proteins as inhibitors of interferon-.gamma. does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with BCRF1 proteins as inhibitors of interferon-.gamma., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and BCRF1 proteins as inhibitors of interferon-.gamma. will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2132691